Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Takeda Pharmaceutical Co LtdTAK55.641.491.263.732.04%1.44%72.25$14.30$9.9422,569$14.34

Detail of Takeda Pharmaceutical Co Ltd

 
CEO
Mr. Christophe Weber
Employees
49281
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Market cap
$6,594B

Company details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$4,413.14B
Cost of goods (CoG)
-$1,492.52B
Gross profit (GP)
$2,920.62B
Operating expense (OE)
-$1,965.93B
Research and development (R&D)
-$735.65B
General and administrative (G&A)
-$1,075.74B
Other (OTH)
-$154.55B
Operating income (OI)
$269.16B
Other income expense (OIE)
-$78.44B
Pretax income (PI)
$54.36B
Tax (TAX)
$95.73B
Net income (NI)
$150.09B
Takeda Pharmaceutical Co Ltd
TAK • XNYS • US
$14.34
-0.70 (-4.62%)
Stock vs Industry average
  • Industry average

Trailing annual dividend rate
$188.00
Payout ratio
195.55%
EPS
$0.26
Margin profit
3.40%
52 week low
$12.60
52 week high
$15.075
50-day simple moving average
$14.36
200-day simple moving average
$14.30
Percent held by insiders
0.01%
Percent held by institutions
2.31%
Dividend yield
1,259.21%

Change of shares

Cash vs Debt

Comparison of selected companies

 
%
Price change
TAK -4.62%
eps change
TAK +5.56%